Nuclear medicine communicationsHumansMaleProstatic NeoplasmsCastration-ResistantLutetium
A standardised attenuated dosing of 177 lutetium-prostate-specific membrane antigen therapy for patients with metastatic castration-resistant prostate carcinoma and preexisting renal impairment.
Dongni Du, Vincent Khoo, Robert Huddart, Yong Du
Published: 202610.1097/MNM.0000000000002078
Abstract
OBJECTIVE: This study analysed the safety and effectiveness of a 20% dose reduction of 177 Lutetium-labelled prostate-specific membrane antigen (PSMA) radioligand therapy in patients with metastatic castration-resistant prostate carcinoma (mCRPC) and…
Preview only. Read the full abstract at the source